The study was conducted to describe the results of BT-A treatment on idiopathic blepharospasm. In the 60 patients, 75 percent of patients with stage III and 25 percent of patients with stage IV. The authors conducted bilateral BT-A injections to 60 patients with the initial dose is 5U/1 the injection site. Injection amount depended on individuals. Medication started to be effective after 110 days, reached the maximum after 7 to 10 days and went off after 3 months. After injection, decreased blepharospasm stage was noticed with 95 percent patients. 45 percent of these had a complete recovery to 0 stage with wide open eyes. Side effects could be cited as 30 percent ptosis, 28 percent dry eyes and 33.3 percent watery eyes . These can appear 2-7 days after injection and disappeared in 1-6 weeks. BT-A was concluded to be safe, effective with mild side effects which were transient.